Who are Levodopa infusion's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Levodopa / Carbidopa, Levodopa and carbidopa, Levodopa Benserazide Madopar, controlled-release levodopa / carbidopa, Levodopa + benserazide, Levodopa/carbidopa/entacapone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/levodopa-infusion.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Levodopa infusion — Competitive Intelligence Brief

Levodopa infusion (Levodopa infusion) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine precursor. Area: Neurology.

marketed Dopamine precursor Dopamine (via AADC conversion) Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Levodopa infusion (Levodopa infusion) — University of Helsinki. Levodopa is converted to dopamine in the brain, replenishing dopamine levels depleted in Parkinson's disease.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Levodopa infusion TARGET	Levodopa infusion	University of Helsinki	marketed	Dopamine precursor	Dopamine (via AADC conversion)
Levodopa / Carbidopa	Levodopa / Carbidopa	Ross D. Zafonte, MD	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Aromatic amino acid decarboxylase (AADC); dopamine pathway
Levodopa and carbidopa	Levodopa and carbidopa	NeuroDerm Ltd.	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Dopamine pathway; aromatic L-amino acid decarboxylase (inhibited by carbidopa)
Levodopa Benserazide Madopar	Levodopa Benserazide Madopar	IRCCS San Raffaele Roma	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Dopamine pathway; aromatic amino acid decarboxylase (inhibited by benserazide)
controlled-release levodopa / carbidopa	controlled-release levodopa / carbidopa	Pfizer	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Aromatic amino acid decarboxylase (AADC); dopamine pathway
Levodopa + benserazide	Levodopa + benserazide	University of Buenos Aires	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Dopamine pathway; aromatic L-amino acid decarboxylase (peripheral inhibition)
Levodopa/carbidopa/entacapone	Levodopa/carbidopa/entacapone	Novartis	marketed	Dopamine precursor with decarboxylase inhibitor and COMT inhibitor	Dopamine pathway; COMT enzyme

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine precursor class)

University of Helsinki · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Levodopa infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/levodopa-infusion. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab